摘要
目的:研究附桂管食通颗粒对脾肾阳虚、顽痰痼血型晚期食管癌患者治疗后42 d生存率、T细胞亚群、食管癌相关肿瘤标志物的影响。方法:纳入9个中心共120例患者,利用区组随机法分为试验1组、试验2组、对照组各40例。试验1组给予附桂管食通颗粒合丁香管食通含化丸;试验2组给予丁香管食通含化丸;对照组给予当归补血汤合桂枝人参汤颗粒,疗程为42 d。比较3组治疗42 d后的生存率、T细胞亚群(CD3^(+)、CD4^(+)、CD8^(+))及癌胚抗原(CEA)、鳞状上皮细胞癌抗原(SCCA),并进行安全性评价。结果:试验1组生存率88.6%、试验2组生存率86.8%、对照组生存率72.2%,3组比较,差异无统计学意义(P>0.05)。治疗后,3组CD4^(+)、CD8^(+)、CEA在时间上差异均有统计学意义(P<0.05),组间差异无统计学意义(P>0.05)。3组CD3^(+)、SCCA在组间和时间上差异均无统计学意义(P>0.05)。结论:附桂管食通颗粒可一定程度提高晚期食管癌患者生存率,并提高机体免疫功能。
Objective:To study the effect of Fugui Guanshitong Granules on survival rates,T lymphocytes and tumor markers related to esophageal cancer in patients with advanced esophageal cancer of spleen-kidney yang deficiency and lingering phlegm and obstinate blood type in 42 days after treatment.Methods:A total of 120 cases of patients from nine centers were included and divided into the trial group1,the trial group 2 and the control group according to the block randomization method,with 40 cases in each group.The trial group 1 was treated with Fugui Guanshitong Granules and Dingxiang Guanshitong Hanhua Pills;the trial group 2 was treated with Dingxiang Guanshitong Hanhua Pills;the control group was treated with Danggui Buxue Decoction and Guizhi Renshen Decoction Granules.All the groups were treated for 42 days.The survival rates,T lymphocytes(CD3^(+) ,CD4^(+) ,CD8^(+) ),carcinoembryonic antigen(CEA),and squamous cell carcinoma antigen(SCCA) in the three groups were compared after 42 days of treatment,and the safety was evaluated.Results:The survival rate was 88.6% in the trial group 1,86.8%in the trial group 2,and 72.2% in the control group,there was no significant difference among the three goups(P>0.05).After treatment,the differences of CD4^(+) ,CD8^(+) ,and CEA in the three groups were significant in time(P<0.05),but there was no significant difference in the comparison among the three groups(P<0.05).There was no significant difference in CD3^(+) and SCCA among the three groups or the comparison of time(P>0.05).Conclusion:Fugui Guanshitong Granules for patients with advanced esophageal cancer can improve their survival rates and immune function.
作者
郑玉玲
陈建设
马纯政
许彦超
陈晓琦
林建州
李军赛
贺文龙
仝新朵
秦善文
张丽菡
ZHENG Yuling;CHEN Jianshe;MA Chunzheng;XU Yanchao;CHEN Xiaoqi;LIN Jianzhou;LI Junsai;HE Wenlong;TONG Xinduo;QIN Shanwen;ZHANG Lihan(He'nan University of Chinese Medicine,Zhengzhou He'nan 450046,China;He'nan Province Hospital of Traditional Chinese Medicine,Zhengzhou He'nan 450003,China;The First Affiliated Hospital of He'nan University of Chinese Medicine,Zhengzhou He'nan 450003,China;Linzhou Hospital of Traditional Chinese Medicine,Linzhou He'nan 456500,China;Jia County of Chinese Medicine,Jiaxian He'nan 467100,China;Zhang Zhongjing Hospital in Nanyang,Nanyang He'nan 473000,China;Third Affiliated Hospital of He'nan University of Traditional Chinese Medicine,Zhengzhou He'nan 450003,China;He'nan Cancer Hospital,Zhengzhou He'nan 450003,China)
出处
《新中医》
CAS
2023年第18期124-130,共7页
New Chinese Medicine
基金
国家中医药百千万人才支持计划-岐黄学者(国中医药人教涵[2018]284号)
全国名老中医药专家传承工作室建设项目(国中医药人教函[2022]75号)
国家中医临床研究基地科研专项(2019JDZX001,2019JDZX028)。
关键词
晚期食管癌
脾肾阳虚
顽痰痼血证
附桂管食通
生存率
T淋巴细胞
Advanced esophageal cancer
Spleen-kidney yang deficiency,lingering phlegm and obstinate blood syndrome
Fugui Guanshitong
Survival rates
T lymphocytes
